Last updated 2026-06-18
- Raised $3.5M funding round, Jul 2022
Total raised
$3.5M
Last: 2022-07
Stage
Seed
Founded
2022
Headcount
2
HQ
Yeruham, Israel
Sector
Health Tech & Life Sciences
About
CanDapi is a breakthrough in delivering medications and cannabinoids to the lungs by dry powder inhalator. It is suitable for any generic and systemic medical powder drugs. It is easy to use for all patients.
Funding history · 1 round · $3.5M total
2022-07
Q&A
- What is CanDapi's primary business?
- CanDapi is developing a breakthrough dry powder inhaler for delivering medications and cannabinoids to the lungs, suitable for various generic and systemic medical powder drugs.
- When was CanDapi founded?
- CanDapi was founded in March 2022.
- What is CanDapi's current operational status?
- CanDapi is currently inactive and ceased to operate in September 2025.
- Where is CanDapi's headquarters located?
- CanDapi's headquarters is in Yeruham, South District, Israel.
- How much funding has CanDapi raised in total?
- CanDapi has raised a total of $3,500,000 USD.
- When was CanDapi's last funding round and who were the investors?
- CanDapi's last funding round was in July 2022, with investments from OurCrowd and Israel Innovation Authority.
- In which sector does CanDapi primarily operate?
- CanDapi operates primarily in the Health Tech & Life Sciences sector.
Team · 2
Founder · Founder
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyMedical CannabisDrug Delivery
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B2C
Tags
drug-deliveryrespiratorymedical-cannabiscannabismedical-devices
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| linkedin.com/company/90895772 |
Identifiers & details
| Founded | 2022-3 |
|---|---|
| Employees (exact) | 2 |
| Status reason | Non Active, Sep 2025 ceased to operate |